Aesther Healthcare Acquisition Corp. Announces Closing of Initial Public Offering and Partial Exercise of Over-Allotment Option

Rhea-AI Summary

Aesther Healthcare Acquisition Corp. (Nasdaq: AEHAU) successfully closed its initial public offering on September 17, 2021, selling 10,000,000 units at $10.00 each, raising approximately $105 million including over-allotments. Each unit consists of a share of Class A common stock and half a redeemable warrant, exercisable at $11.50. Trading for these units began on September 15, 2021. Aesther, a blank check company, aims to pursue business combinations primarily in the pharmaceutical and medical device sectors.

Positive

• Raised approximately $105 million from the IPO, providing ample capital for future acquisitions.
• Focused on the lucrative pharmaceutical and medical device sectors for potential mergers and acquisitions.

Negative

• None.

New York, NY, Sept. 17, 2021 (GLOBE NEWSWIRE) -- Aesther Healthcare Acquisition Corp. (Nasdaq: AEHAU) (the “Company”) announced today the closing of its initial public offering of 10,000,000 units at $10.00 per unit. Each unit consists of one share of the Company’s Class A common stock and one half of one redeemable warrant, each whole warrant entitling the holder thereof to purchase one share of Class A common stock at a price of $11.50 per share. Only whole warrants are exercisable. The underwriters partially exercised their over-allotment option for an additional 500,000 units at the time of the closing of the Offering. As a result, the aggregate gross proceeds of the offering, including the over-allotment, are $105,000,000, prior to deducting underwriting discounts, commissions and other offering expenses.

The Company’s units began trading on the Nasdaq Global Market on September 15, 2021 under the ticker symbol “AEHAU.” Once the securities comprising the units begin separate trading, the shares of Class A common stock and warrants are expected to be listed on the Nasdaq Global Market under the ticker symbols “AEHA” and “AEHAW”, respectively.

The Company is a blank check company formed for the purpose of effecting a merger, capital stock exchange, asset acquisition, stock purchase, reorganization or similar business combination with one or more businesses. While the Company may pursue an initial business combination target in any business or industry, it intends to focus on the pharmaceutical and medical device sectors.

EF Hutton, division of Benchmark Investments, LLC, acted as sole book running manager for the offering.

The offering was made only by means of a prospectus. Copies of the prospectus may be obtained from EF Hutton, division of Benchmark Investments, LLC, Attn: Syndicate Department, 590 Madison Ave., 39th Floor, New York, New York 10022, by telephone at (212) 404-7002, by fax at (646) 861-4697, or by email at syndicate@efhuttongroup.com, or by visiting EDGAR on the SEC’s website at www.sec.gov.

A registration statement relating to these securities was declared effective by the Securities and Exchange Commission on September 14, 2021. This press release shall not constitute an offer to sell or the solicitation of an offer to buy any of the securities described herein, nor shall there be any sale of these securities in any state or jurisdiction in which such an offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

FORWARD-LOOKING STATEMENTS

This press release contains statements that constitute “forward-looking statements,” including with respect to the initial public offering and the anticipated use of the net proceeds. No assurance can be given that the net proceeds of the offering will be used as indicated. Forward-looking statements are subject to numerous conditions, many of which are beyond the control of the Company, including those set forth in the Risk Factors section of the Company's registration statement and final prospectus for the offering filed with the Securities and Exchange Commission (“SEC”). Copies are available on the SEC's website, www.sec.gov. The Company undertakes no obligation to update these statements for revisions or changes after the date of this release, except as required by law.

Contact

Aesther Healthcare Acquisition Corp.
515 Madison Ave
Suite 8078
New York, NY 10022
Attn: Suren Ajjarapu
Chairman & CEO
suren@aestherhealthcarespac.com
(646) 908-2658

FAQ

What is Aesther Healthcare Acquisition Corp's IPO date?

Aesther Healthcare Acquisition Corp's initial public offering was closed on September 17, 2021.

How much capital did Aesther Healthcare Acquisition Corp raise in its IPO?

Aesther Healthcare Acquisition Corp raised approximately $105 million from its IPO, including over-allotments.

What will Aesther Healthcare Acquisition Corp do with the funds from the IPO?

The funds will be used to pursue mergers, acquisitions, or similar business combinations, focusing on the pharmaceutical and medical device sectors.

What are the ticker symbols for Aesther Healthcare Acquisition Corp's securities?

The units trade under the ticker symbol AEHAU, the Class A common stock under AEHA, and the warrants under AEHAW.